The MarketWatch News Department was not involved in the creation of this content.-- Newly discovered drug leverages the power of Pattern Discovery Engine(TM) (PDE) and is an exten ...
Alto Neuroscience secures $120M to advance novel depression therapy ALTO-207 through Phase 3 trials, aiming for FDA ...
Eli Lilly and Co on Thursday issued a public warning about potential safety risks linked to compounded tirzepatide products that are mixed with vitamin B12. The company said internal testing detected ...
6h
GNQ Insilico Inc. to go Public Through Business Combination With IB Acquisition Corp. (NASDAQ: IBAC)
GNQ Insilico Inc. (“GNQ” or the “Company”), a corporation formed under the federal laws of Canada, and IB Acquisition Corp. (Nasdaq: IBAC) (“IBAC”), a Nevada special purpose acquisition company, today ...
FDA confirmed givastomig’s potential eligibility for an accelerated approval pathwayNovaBridge expects to initiate a registrational Phase 3 ...
Roche's Ashley Magargee, chief executive of its Genentech unit, said on Monday the company is striving to build a portfolio of obesity medicines that are both tolerable in terms of side effects ...
By Michele Gershberg and Michael Erman PHILADELPHIA, March 16 (Reuters) - The CEO of Roche's Genentech unit, Ashley Magargee, ...
SAN FRANCISCO, March 16, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today reported financial results for the fourth quarter and full year 2025 and provided an update on the company’s recent ...
Losing locks? Don’t wig out just yet. Scientists may have found a hair loss treatment that works better than the top drugs already on the market. The key is that it’s not one drug but three — and it ...
Roche's Ashley Magargee, chief executive of its Genentech unit, said on Monday the company is striving to build a portfolio of obesity medicines that are both tolerable in terms of side effects ...
In 2025, CytomX remained focused on controlling costs and efficiently progressing its pipeline programs. Total operating expense for 2025 was $98.6 million compared to $113.1 million for 2024, a ...
CLEVELAND, Ohio — A shift toward personalized treatment for breast cancer, ways to help patients live longer without their cancer worsening and a shorter but equally effective treatment for a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results